Back to Search
Start Over
EGFRT790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
- Source :
- Journal of Thoracic Oncology; May 2018, Vol. 13 Issue: 5 p727-731, 5p
- Publication Year :
- 2018
-
Abstract
- Dacomitinib was superior to gefitinib in terms of progression-free survival in patients with EGFR-mutant lung cancer in a recent ARCHER 1050 trial. However, despite a marked initial response, lung cancers eventually acquire resistance to these inhibitors. This study aimed to elucidate the mechanisms of acquired resistance to dacomitinib in vitro.
Details
- Language :
- English
- ISSN :
- 15560864 and 15561380
- Volume :
- 13
- Issue :
- 5
- Database :
- Supplemental Index
- Journal :
- Journal of Thoracic Oncology
- Publication Type :
- Periodical
- Accession number :
- ejs44781046
- Full Text :
- https://doi.org/10.1016/j.jtho.2018.01.009